{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:46:09Z","timestamp":1786981569568,"version":"build-2736575974"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is the most common type of human dementia and is responsible for over 60% of diagnosed dementia cases worldwide. Abnormal deposition of \u03b2-amyloid and the accumulation of neurofibrillary tangles have been recognised as the two pathological hallmarks targeted by AD diagnostic imaging as well as therapeutics. With the progression of pathological studies, the two hallmarks and their related pathways have remained the focus of researchers who seek for AD diagnostic and therapeutic strategies in the past decades. In this work, we reviewed the development of the AD biomarkers and their corresponding target-specific small molecule drugs for both diagnostic and therapeutic applications, underlining their success, failure, and future possibilities.<\/jats:p>","DOI":"10.1007\/s11064-024-04178-w","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T14:03:16Z","timestamp":1717682596000},"page":"2273-2302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer\u2019s Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy"],"prefix":"10.1007","volume":"49","author":[{"given":"Li","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"4178_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS (2014) Amyloid-\u03b2 and tau: the trigger and bullet in alzheimer disease pathogenesis. JAMA Neurol 71:505\u2013508","journal-title":"JAMA Neurol"},{"key":"4178_CR2","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1126\/science.1058189","volume":"293","author":"J Lewis","year":"2001","unstructured":"Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen S-H, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487\u20131491","journal-title":"Science"},{"key":"4178_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1126\/science.1062097","volume":"293","author":"J G\u00f6tz","year":"2001","unstructured":"G\u00f6tz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A\u03b242 fibrils. Science 293:1491\u20131495","journal-title":"Science"},{"key":"4178_CR4","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.ajpath.2012.08.012","volume":"181","author":"K Leroy","year":"2012","unstructured":"Leroy K, Ando K, Laporte V, Dedecker R, Suain V, Authelet M, H\u00e9raud C, Pierrot N, Yilmaz Z, Octave JN, Brion JP (2012) Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP\/PS1 Mice. Am J Pathol 181:1928\u20131940","journal-title":"Am J Pathol"},{"key":"4178_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, N\u00e5gren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754\u2013760","journal-title":"Neurology"},{"key":"4178_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-40013-40026-y","author":"L Mosconi","year":"2013","unstructured":"Mosconi L (2013) Glucose metabolism in normal aging and Alzheimer\u2019s disease: methodological and physiological considerations for PET studies. Clin Transl Imaging. https:\/\/doi.org\/10.1007\/s40336-40013-40026-y","journal-title":"Clin Transl Imaging"},{"key":"4178_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1196\/annals.1427.007","volume":"1147","author":"L Mosconi","year":"2008","unstructured":"Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer\u2019s disease. Ann New York Acad Sci 1147:180\u2013195","journal-title":"Ann New York Acad Sci"},{"key":"4178_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000088558","volume":"20","author":"ALW Bokde","year":"2005","unstructured":"Bokde ALW, Teipel SJ, Drzezga A, Thissen J, Bartenstein P, Dong W, Leinsinger G, Born C, Schwaiger M, Moeller HJ, Hampel H (2005) Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 20:352\u2013357","journal-title":"Dement Geriatr Cogn Disord"},{"key":"4178_CR9","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/brain\/awh539","volume":"128","author":"EJ Kim","year":"2005","unstructured":"Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, Kim SE, Lee KH, Na DL (2005) Glucose metabolism in early onset versus late onset Alzheimer\u2019s disease: an SPM analysis of 120 patients. Brain 128:1790\u20131801","journal-title":"Brain"},{"key":"4178_CR10","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/brain\/awl178","volume":"129","author":"H Engler","year":"2006","unstructured":"Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, L\u00e5ngstr\u00f6m B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease. Brain 129:2856\u20132866","journal-title":"Brain"},{"key":"4178_CR11","doi-asserted-by":"publisher","DOI":"10.1039\/C29690000077","author":"T Ido","year":"1978","unstructured":"Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, Kuhl DE (1978) Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C\u20132-deoxy-2-fluoro-D-glucose. J Label Comp Radiopharm. https:\/\/doi.org\/10.1039\/C29690000077","journal-title":"J Label Comp Radiopharm"},{"key":"4178_CR12","doi-asserted-by":"publisher","DOI":"10.1039\/C29690000077","author":"J Pac\u00e1k","year":"1969","unstructured":"Pac\u00e1k J, To\u010d\u00edk Z, \u010cern\u00fd M (1969) Synthesis of 2-deoxy-2-fluoro-D-glucose. J Chem Soc D: Chem Commun. https:\/\/doi.org\/10.1039\/C29690000077","journal-title":"J Chem Soc D: Chem Commun"},{"key":"4178_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-019-0473-4","volume":"11","author":"SP Caminiti","year":"2019","unstructured":"Caminiti SP, Sala A, Iaccarino L, Beretta L, Pilotto A, Gianolli L, Iannaccone S, Magnani G, Padovani A, Ferini-Strambi L, Perani D (2019) Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. Alzheimer\u2019s Res Ther 11:20","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"4178_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/jcp.17.3.213","volume":"17","author":"JC McAlpine","year":"1964","unstructured":"McAlpine JC, Bancroft JD (1964) A histological study of hyaline deposits in laryngeal, aural, and nasal polyps and their differentiation from amyloid. J Clin Pathol 17:213\u2013219","journal-title":"J Clin Pathol"},{"key":"4178_CR15","first-page":"371","volume":"50","author":"GK Klintworth","year":"1967","unstructured":"Klintworth GK (1967) Lattice corneal dystrophy. an inherited variety of amyloidosis restricted to the cornea. Am J Pathol 50:371\u2013399","journal-title":"Am J Pathol"},{"key":"4178_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/jcp.19.2.103","volume":"19","author":"ED Williams","year":"1966","unstructured":"Williams ED, Brown CL, Doniach I (1966) Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid. J Clin Pathol 19:103\u2013113","journal-title":"J Clin Pathol"},{"key":"4178_CR17","first-page":"373","volume":"113","author":"SH Yen","year":"1983","unstructured":"Yen SH, Gaskin F, Fu SM (1983) Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class. Am J Pathol 113:373\u2013381","journal-title":"Am J Pathol"},{"key":"4178_CR18","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1073\/pnas.83.8.2662","volume":"83","author":"A Roher","year":"1986","unstructured":"Roher A, Wolfe D, Palutke M, KuKuruga D (1986) Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci USA 83:2662\u20132666","journal-title":"Proc Natl Acad Sci USA"},{"key":"4178_CR19","volume-title":"Thioflavin derivatives for use in antemortem diagnosis of alzheimer\u2019s disease and in vivo imaging and prevention of amyloid deposition","author":"W Klunk","year":"2002","unstructured":"Klunk W, Mathis C, Wang Y (2002) Thioflavin derivatives for use in antemortem diagnosis of Alzheimer\u2019s disease and in vivo imaging and prevention of amyloid deposition. University of Pittsburgh, Pittsburgh"},{"key":"4178_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr\u00f6m M, Savitcheva I, Huang GF, Estrada S, Aus\u00e9n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L\u00e5ngstr\u00f6m B (2004) Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Ann Neurol 55:306\u2013319","journal-title":"Ann Neurol"},{"key":"4178_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.parkreldis.2010.08.021","volume":"16","author":"P Jokinen","year":"2010","unstructured":"Jokinen P, Scheinin NM, Aalto S, N\u00e5gren K, Savisto N, Parkkola R, Rokka J, Haaparanta M, R\u00f6ytt\u00e4 M, Rinne JO (2010) [11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinson\u2019s disease with and without dementia. Parkinsonism Relat Disord 16:666\u2013670","journal-title":"Parkinsonism Relat Disord"},{"key":"4178_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H (2014) [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 41:290\u2013300","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"4178_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, Bormans G, Brooks DJ, Vandenberghe R (2009) Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50(8):1251\u20139","journal-title":"J Nucl Med"},{"issue":"3","key":"4178_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68(3):319\u2013329","journal-title":"Ann neurol."},{"key":"4178_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S (2015) Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 72:287\u2013294","journal-title":"JAMA Neurol"},{"key":"4178_CR26","doi-asserted-by":"publisher","first-page":"12740","DOI":"10.1021\/ja0167147","volume":"123","author":"HF Kung","year":"2001","unstructured":"Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Pl\u00f6ssl K (2001) Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 123:12740\u201312741","journal-title":"J Am Chem Soc"},{"key":"4178_CR27","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1021\/jm050166g","volume":"48","author":"W Zhang","year":"2005","unstructured":"Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF (2005) F-18 stilbenes as PET imaging agents for detecting \u03b2-amyloid plaques in the brain. J Med Chem 48:5980\u20135988","journal-title":"J Med Chem"},{"key":"4178_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.nucmedbio.2005.06.001","volume":"32","author":"W Zhang","year":"2005","unstructured":"Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF (2005) F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting A\u03b2 aggregates in the brain. Nucl Med Biol 32:799\u2013809","journal-title":"Nucl Med Biol"},{"key":"4178_CR29","volume-title":"Stilbene derivatives and their use for binding and imaging amyloid plaquES","author":"HF Kung","year":"2006","unstructured":"Kung HF, Kung MP, Zhuang ZP (2006) Stilbene derivatives and their use for binding and imaging amyloid plaquES. Pubchem, Bethesda"},{"key":"4178_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2015.10.007","author":"JM Mountz","year":"2015","unstructured":"Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA (2015) Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer\u2019s subjects. NeuroImag Clin. https:\/\/doi.org\/10.1016\/j.nicl.2015.10.007","journal-title":"NeuroImag Clin"},{"issue":"1","key":"4178_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, Mintun MA (2013) Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 54(1):70\u20137","journal-title":"J of Nucl Med."},{"key":"4178_CR32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1212\/01.wnl.0000260969.94695.56","volume":"68","author":"MN Kemppainen","year":"2007","unstructured":"Kemppainen MN, Aalto AS, Wilson OI, N\u00e5gren OK, Helin OS, Br\u00fcck OA, Oikonen OV, Kailaj\u00e4rvi OM, Scheinin OM, Viitanen OM, Parkkola OR, Rinne OJ (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603\u20131606","journal-title":"Neurology"},{"key":"4178_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.1570","volume":"107","author":"JE Ahn","year":"2020","unstructured":"Ahn JE, Carrieri C, Dela Cruz F, Fullerton T, Hajos-Korcsok E, He P, Kantaridis C, Leurent C, Liu R, Mancuso J, Mendes da Costa L, Qiu R (2020) Pharmacokinetic and pharmacodynamic effects of a \u03b3-secretase modulator, PF-06648671, on CSF amyloid-\u03b2 peptides in randomized phase I studies. Clin Pharmacol Ther 107:211\u2013220","journal-title":"Clin Pharmacol Ther"},{"key":"4178_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1021\/acsmedchemlett.0c00109","volume":"11","author":"H Ratni","year":"2020","unstructured":"Ratni H, Alker A, Bartels B, Bissantz C, Chen W, Gerlach I, Limberg A, Lu M, Neidhart W, Pichereau S, Reutlinger M, Rodriguez-Sarmiento RM, Jakob-Roetne R, Schmitt G, Zhang E, Baumann K (2020) Discovery of RO7185876, a highly potent \u03b3-secretase modulator (GSM) as a potential treatment for Alzheimer\u2019s disease. ACS Med Chem Lett 11:1257\u20131268","journal-title":"ACS Med Chem Lett"},{"key":"4178_CR35","doi-asserted-by":"publisher","first-page":"1279740","DOI":"10.3389\/fnmol.2023.1279740","volume":"16","author":"G Nordvall","year":"2023","unstructured":"Nordvall G, Lundkvist J, Sandin J (2023) Gamma-secretase modulators: a promising route for the treatment of Alzheimer\u2019s disease. Front Mol Neurosci 16:1279740","journal-title":"Front Mol Neurosci"},{"key":"4178_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/ADR-210296","volume":"5","author":"AC Lo","year":"2021","unstructured":"Lo AC, Evans CD, Mancini M, Wang H, Shcherbinin S, Lu M, Natanegara F, Willis BA (2021) Phase II (NAVIGATE-AD study) results of LY3202626 effects on patients with mild Alzheimer\u2019s disease dementia. J Alzheimers Dis Rep 5:321\u2013336","journal-title":"J Alzheimers Dis Rep"},{"key":"4178_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3233\/JAD-190228","volume":"71","author":"R Qiu","year":"2019","unstructured":"Qiu R, Ahn JE, Alexander R, Brodney MA, He P, Leurent C, Mancuso J, Margolin RA, Tankisheva E, Chen D (2019) Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of PF-06751979, a potent and selective oral bace1 inhibitor: results from phase i studies in healthy adults and healthy older subjects. J Alzheimers Dis 71:581\u2013595","journal-title":"J Alzheimers Dis"},{"key":"4178_CR38","doi-asserted-by":"publisher","first-page":"e072340","DOI":"10.1002\/alz.072340","volume":"19","author":"B Decourt","year":"2023","unstructured":"Decourt B, Wilson J, Dumitrescu L, Ritter A, Sabbagh M (2023) Mclena-1: a phase II clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to Alzheimer\u2019s disease. Interim Progress Alzheimer\u2019s Dementia 19:e072340","journal-title":"Interim Progress Alzheimer\u2019s Dementia"},{"key":"4178_CR39","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","volume":"83","author":"K Endres","year":"2014","unstructured":"Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, T\u00fcscher O, Fellgiebel A (2014) Increased CSF APPs-\u03b1 levels in patients with Alzheimer disease treated with acitretin. Neurology 83:1930\u20131935","journal-title":"Neurology"},{"key":"4178_CR40","first-page":"e12001","volume":"6","author":"J Kutzsche","year":"2020","unstructured":"Kutzsche J, J\u00fcrgens D, Willuweit A, Adermann K, Fuchs C, Simons S, Windisch M, H\u00fcmpel M, Rossberg W, Wolzt M, Willbold D (2020) Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: a single and multiple ascending dose phase I study. Alzheimers Dement NY 6:e12001","journal-title":"Alzheimers Dement NY"},{"key":"4178_CR41","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"R Vassar","year":"2009","unstructured":"Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer\u2019s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29:12787\u201312794","journal-title":"J Neurosci"},{"key":"4178_CR42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrm2009","volume":"7","author":"SJ Bray","year":"2006","unstructured":"Bray SJ (2006) Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7:678\u2013689","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4178_CR43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369:341\u2013350","journal-title":"N Engl J Med"},{"key":"4178_CR44","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302:2557\u20132564","journal-title":"JAMA"},{"key":"4178_CR45","volume-title":"RG6289, a new \u03b3-secretase modulator for the treatment of Alzheimer\u2019s disease: Dose selection for a Phase II trial based on population PK\/PD modeling","author":"D Lott AP","year":"2023","unstructured":"Lott AP D, Alam M, Cantrill C, Croney R, Alcaraz F, Rodr\u00edguez Sarmiento RM, Lindemann L, Mueller L, Mueggler T, Vardar T, Tortelli R, Sturm S, Gerlach I (2023) RG6289, a new \u03b3-secretase modulator for the treatment of Alzheimer\u2019s disease: dose selection for a Phase II trial based on population PK\/PD modeling. Roche, Basel"},{"key":"4178_CR46","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves F, Kalinowski P, Ayton S (2023) Accelerated brain volume loss caused by anti\u2013\u03b2-amyloid drugs. Neurology 100:e2114\u2013e2124","journal-title":"Neurology"},{"key":"4178_CR47","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K (2016) Plasma tau in Alzheimer disease. Neurology 87:1827\u20131835","journal-title":"Neurology"},{"key":"4178_CR48","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","volume":"72","author":"MD Weingarten","year":"1975","unstructured":"Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72:1858\u20131862","journal-title":"Proc Natl Acad Sci USA"},{"key":"4178_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.702788","author":"B Boyarko","year":"2021","unstructured":"Boyarko B, Hook V (2021) Human tau isoforms and proteolysis for production of toxic tau fragments in neurodegeneration. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2021.702788","journal-title":"Front Neurosci"},{"key":"4178_CR50","doi-asserted-by":"publisher","first-page":"E8187","DOI":"10.1073\/pnas.1616344113","volume":"113","author":"AL Woerman","year":"2016","unstructured":"Woerman AL, Aoyagi A, Patel S, Kazmi SA, Lobach I, Grinberg LT, McKee AC, Seeley WW, Olson SH, Prusiner SB (2016) Tau prions from Alzheimer\u2019s disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proc Natl Acad Sci USA 113:E8187\u2013E8196","journal-title":"Proc Natl Acad Sci USA"},{"key":"4178_CR51","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1016\/j.jmb.2018.09.010","volume":"430","author":"H Kumar","year":"2018","unstructured":"Kumar H, Udgaonkar JB (2018) Mechanistic and structural origins of the asymmetric barrier to prion-like cross-seeding between Tau-3R and Tau-4R. J Mol Biol 430:5304\u20135312","journal-title":"J Mol Biol"},{"key":"4178_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-2008-14101","volume":"14","author":"M Espinoza","year":"2008","unstructured":"Espinoza M, de Silva R, Dickson DW, Davies P (2008) Differential incorporation of tau isoforms in Alzheimer\u2019s disease. J Alzheimers Dis 14:1\u201316","journal-title":"J Alzheimers Dis"},{"key":"4178_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00401-023-02574-0","volume":"146","author":"M Manca","year":"2023","unstructured":"Manca M, Standke HG, Browne DF, Huntley ML, Thomas OR, Orr\u00fa CD, Hughson AG, Kim Y, Zhang J, Tatsuoka C, Zhu X, Hiniker A, Coughlin DG, Galasko D, Kraus A (2023) Tau seeds occur before earliest Alzheimer\u2019s changes and are prevalent across neurodegenerative diseases. Acta Neuropathol 146:31\u201350","journal-title":"Acta Neuropathol"},{"key":"4178_CR54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/JAD-2007-12410","volume":"12","author":"J Luna-Mu\u00f1oz","year":"2008","unstructured":"Luna-Mu\u00f1oz J, Ch\u00e1vez-Mac\u00edas L, Garc\u00eda-Sierra F, Mena R (2008) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer\u2019s disease. J Alzheimers Dis 12:365\u2013375","journal-title":"J Alzheimers Dis"},{"key":"4178_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00247","author":"NI Luna-Viramontes","year":"2020","unstructured":"Luna-Viramontes NI, Campa-C\u00f3rdoba BB, Ontiveros-Torres M\u00c1, Harrington CR, Villanueva-Fierro I, Guadarrama-Ort\u00edz P, Garc\u00e9s-Ram\u00edrez L, de la Cruz F, Hernandes-Alejandro M, Mart\u00ednez-Robles S, Gonz\u00e1lez-Ballesteros E, Pacheco-Herrero M, Luna-Mu\u00f1oz J (2020) PHF-core tau as the potential initiating event for tau pathology in Alzheimer\u2019s disease. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2020.00247","journal-title":"Front Cell Neurosci"},{"key":"4178_CR56","doi-asserted-by":"publisher","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","volume":"110","author":"BB Holmes","year":"2013","unstructured":"Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110:E3138-3147","journal-title":"Proc Natl Acad Sci USA"},{"key":"4178_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neulet.2015.04.021","volume":"597","author":"SP Pallo","year":"2015","unstructured":"Pallo SP, Johnson GVW (2015) Tau facilitates A\u03b2-induced loss of mitochondrial membrane potential independent of cytosolic calcium fluxes in mouse cortical neurons. Neurosci Lett 597:32\u201337","journal-title":"Neurosci Lett"},{"key":"4178_CR58","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1242\/jcs.1125880","volume":"126","author":"ME Seward","year":"2013","unstructured":"Seward ME, Swanson E, Norambuena A, Reimann A, Cochran JN, Li R, Roberson ED, Bloom GS (2013) Amyloid-\u03b2 signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer\u2019s disease. J Cell Sci 126:1278\u20131286","journal-title":"J Cell Sci"},{"key":"4178_CR59","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1038\/emboj.2013.207","volume":"32","author":"H Zempel","year":"2013","unstructured":"Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, Mandelkow EM (2013) Amyloid-\u03b2 oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32:2920\u20132937","journal-title":"EMBO J"},{"key":"4178_CR60","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","volume":"60","author":"P Giannakopoulos","year":"2003","unstructured":"Giannakopoulos P, Herrmann FR, Bussi\u00e8re T, Bouras C, K\u00f6vari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease. Neurology 60:1495\u20131500","journal-title":"Neurology"},{"key":"4178_CR61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1523\/JNEUROSCI.21-24-j0004.2001","volume":"21","author":"ED Agdeppa","year":"2001","unstructured":"Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer\u2019s disease. J Neurosci 21:189","journal-title":"J Neurosci"},{"key":"4178_CR62","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1471-4159.2009.05996.x","volume":"109","author":"PW Thompson","year":"2009","unstructured":"Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, Shipley NJ, Libri V, Lockhart A (2009) Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer\u2019s disease pathologies. J Neurochem 109:623\u2013630","journal-title":"J Neurochem"},{"key":"4178_CR63","doi-asserted-by":"publisher","first-page":"E2039","DOI":"10.1073\/pnas.1409952112","volume":"112","author":"JR Barrio","year":"2015","unstructured":"Barrio JR, Small GW, Wong KP, Huang SC, Liu J, Merrill DA, Giza CC, Fitzsimmons RP, Omalu B, Bailes J, Kepe V (2015) In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging. Proc Natl Acad Sci 112:E2039\u2013E2047","journal-title":"Proc Natl Acad Sci"},{"key":"4178_CR64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/JAD-171152","volume":"65","author":"ST Chen","year":"2018","unstructured":"Chen ST, Siddarth P, Merrill DA, Martinez J, Emerson ND, Liu J, Wong KP, Satyamurthy N, Giza CC, Huang SC, Fitzsimmons RP, Bailes J, Omalu B, Barrio JR, Small GW (2018) FDDNP-PET tau brain protein binding patterns in military personnel with suspected chronic traumatic encephalopathy1. J Alzheimers Dis 65:79\u201388","journal-title":"J Alzheimers Dis"},{"issue":"suppl 3","key":"4178_CR65","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JAD-2011-0008","volume":"26","author":"J Shin","year":"2011","unstructured":"Shin J, Kepe V, Barrio JR, Small GW (2011) The merits of FDDNP-PET imaging in Alzheimer\u2019s disease. J Alzheimers Dis 26(suppl 3):135\u2013145","journal-title":"J Alzheimers Dis"},{"key":"4178_CR66","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.114.139550","volume":"55","author":"H Hashimoto","year":"2014","unstructured":"Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, Shiomi S, Muto M, Ito T, Furutsuka K, Yamasaki T, Yui J, Xie L, Ono M, Hatori A, Nemoto K, Suhara T, Higuchi M, Zhang MR (2014) Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med 55:1532\u20131538","journal-title":"J Nucl Med"},{"key":"4178_CR67","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1016\/j.bmcl.2015.08.053","volume":"25","author":"M Wang","year":"2015","unstructured":"Wang M, Gao M, Xu Z, Zheng QH (2015) Synthesis of a PET tau tracer [11C]PBB3 for imaging of Alzheimer\u2019s disease. Bioorg Med Chem Lett 25:4587\u20134592","journal-title":"Bioorg Med Chem Lett"},{"key":"4178_CR68","first-page":"764","volume":"140","author":"M Ono","year":"2017","unstructured":"Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, Dickson DW, Trojanowski JQ, Lee VMY, Yoshida M, Hozumi I, Yoshiyama Y, van Swieten JC, Nordberg A, Suhara T, Zhang M-R, Higuchi M (2017) Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140:764\u2013780","journal-title":"Brain"},{"key":"4178_CR69","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","volume":"54","author":"N Okamura","year":"2013","unstructured":"Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54:1420\u20131427","journal-title":"J Nucl Med"},{"key":"4178_CR70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/biom6010007","volume":"6","author":"R Harada","year":"2016","unstructured":"Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y (2016) Characteristics of tau and its ligands in PET imaging. Biomolecules 6:7\u20137","journal-title":"Biomolecules"},{"key":"4178_CR71","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","volume":"57","author":"R Harada","year":"2016","unstructured":"Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Tago T, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y (2016) 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med 57:208\u2013214","journal-title":"J Nucl Med"},{"key":"4178_CR72","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1212\/WNL.0000000000003375","volume":"87","author":"A Kikuchi","year":"2016","unstructured":"Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Ezura M, Kobayashi M, Tano O, Mugikura S, Iwata R, Ishiki A, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M (2016) In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 87:2309\u20132316","journal-title":"Neurology"},{"key":"4178_CR73","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/jlcr.3425","volume":"59","author":"DP Holt","year":"2016","unstructured":"Holt DP, Ravert HT, Dannals RF (2016) Synthesis and quality control of [18F] T807 for tau PET imaging. J Labelled Compd Radiopharm 59:411\u2013415","journal-title":"J Labelled Compd Radiopharm"},{"key":"4178_CR74","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"CF Xia","year":"2013","unstructured":"Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Su H, Szardenings AK, Walsh JC, Wang E, Yu C, Zhang W, Zhao T, Kolb HC (2013) [18F]T807, a novel tau positron emission tomography imaging agent for\u00a0Alzheimer\u2019s disease. Alzheimer\u2019s Dement 9:666\u2013676","journal-title":"Alzheimer\u2019s Dementia"},{"key":"4178_CR75","first-page":"1244","volume":"55","author":"M Gao","year":"2014","unstructured":"Gao M, Wang M, Zheng Q-H (2014) Fully automated synthesis of [18F]-T808, a PET tau tracer for Alzheimer\u2019s disease. J Nucl Med 55:1244","journal-title":"J Nucl Med"},{"key":"4178_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, Kantarci K, Boeve BF, Pandey MK, Bruinsma T, Knopman DS, Jones DT, Petrucelli L, Cook CN, Graff-Radford NR, Dickson DW, Petersen RC, Jack CR Jr, Murray ME (2016) An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 4:58\u201358","journal-title":"Acta Neuropathol Commun"},{"key":"4178_CR77","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/JAD-2012-120712","volume":"31","author":"W Zhang","year":"2012","unstructured":"Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Szardenings AK, Wang E, Walsh JC, Xia C, Yu C, Zhao T, Kolb HC (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 31:601\u2013612","journal-title":"J Alzheimers Dis"},{"key":"4178_CR78","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.2174\/0929867043364784","volume":"11","author":"DE Edmondson","year":"2004","unstructured":"Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F (2004) Structure and mechanism of monoamine oxidase. Curr Med Chem 11:1983\u20131993","journal-title":"Curr Med Chem"},{"key":"4178_CR79","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/mds.26813","volume":"32","author":"R Smith","year":"2017","unstructured":"Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, H\u00e4gerstr\u00f6m D, J\u00f6gi J, Borroni E, Sch\u00f6ll M, Honer M, Hansson O (2017) Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord 32:108\u2013114","journal-title":"Mov Disord"},{"key":"4178_CR80","first-page":"232","volume":"10","author":"L Lemoine","year":"2018","unstructured":"Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A (2018) Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimer\u2019s Dementia: Diagn, Assess Dis Monit 10:232\u2013236","journal-title":"Alzheimer\u2019s Dementia: Diagn, Assess Dis Monit"},{"key":"4178_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.aquatox.2015.11.016","volume":"171","author":"S Faltermann","year":"2016","unstructured":"Faltermann S, Pr\u00e9t\u00f4t R, Pernthaler J, Fent K (2016) Comparative effects of nodularin and microcystin-LR in zebrafish: 1. Uptake by organic anion transporting polypeptide Oatp1d1 (Slco1d1). Aquat Toxicol 171:69\u201376","journal-title":"Aquat Toxicol"},{"key":"4178_CR82","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2967\/jnumed.117.197426","volume":"59","author":"R Harada","year":"2018","unstructured":"Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, Tago T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Nakamura T, Yoshikawa T, Iwata R, Tashiro M, Sasano H, Kitamoto T, Yanai K, Arai H, Kudo Y, Okamura N (2018) Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med 59:671\u2013674","journal-title":"J Nucl Med"},{"key":"4178_CR83","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mds.27271","volume":"33","author":"C Vermeiren","year":"2018","unstructured":"Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade JP, Citron M, Mercier J, Hannestad J, Gillard M (2018) The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord 33:273\u2013281","journal-title":"Mov Disord"},{"key":"4178_CR84","first-page":"487","volume":"60","author":"L Drake","year":"2019","unstructured":"Drake L, Pham J, Brooks A, Koeppe R, Scott P (2019) MAO-B inhibitor deprenyl displaces [18F] AV1451 binding on human brain tissue sections and alters uptake in nonhuman primate brain. J Nucl Med 60:487","journal-title":"J Nucl Med"},{"key":"4178_CR85","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, Connolly B, Gantert L, Haley H, Holahan M, Purcell M, Riffel K, Lohith TG, Coleman P, Soriano A, Ogawa A, Xu S, Zhang X, Joshi E, Della Rocca J, Hesk D, Schenk DJ, Evelhoch JL (2016) Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med 57:1599\u20131606","journal-title":"J Nucl Med"},{"key":"4178_CR86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nucmedbio.2022.04.001","volume":"114\u2013115","author":"A Kallinen","year":"2022","unstructured":"Kallinen A, Kassiou M (2022) Tracer development for PET imaging of proteinopathies. Nucl Med Biol 114\u2013115:115\u2013127","journal-title":"Nucl Med Biol"},{"key":"4178_CR87","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","volume":"7","author":"C Aguero","year":"2019","unstructured":"Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, Marquie M, Johnson KA, El Fakhri G, Frosch MP, Gomez-Isla T (2019) Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun 7:37","journal-title":"Acta Neuropathol Commun"},{"key":"4178_CR88","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2967\/jnumed.117.196741","volume":"59","author":"M Honer","year":"2018","unstructured":"Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, Valentine H, Dannals RF, Wong DF, Borroni E (2018) Preclinical evaluation of (18)F-RO6958948, (11)C-RO6931643, and (11)C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J Nucl Med 59:675\u2013681","journal-title":"J Nucl Med"},{"key":"4178_CR89","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/RLU.0000000000003261","volume":"45","author":"M Oh","year":"2020","unstructured":"Oh M, Oh SJ, Lee SJ, Oh JS, Roh JH, Chung SJ, Lee JH, Lee CS, Kim JS (2020) Clinical evaluation of 18F-PI-2620 as a potent PET radiotracer imaging tau protein in Alzheimer disease and other neurodegenerative diseases compared with 18F-THK-5351. Clin Nucl Med 45:841\u2013847","journal-title":"Clin Nucl Med"},{"key":"4178_CR90","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1177\/0271678X211031035","volume":"41","author":"SL Baker","year":"2021","unstructured":"Baker SL, Provost K, Thomas W, Whitman A, Janabi M, Schmidt ME, Timmers M, Kolb HC, Rabinovici GD, Jagust WJ (2021) Evaluation of [18F]-JNJ-64326067-AAA tau PET tracer in humans. J Cereb Blood Flow Metab 41:3302\u20133313","journal-title":"J Cereb Blood Flow Metab"},{"key":"4178_CR91","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","volume":"46","author":"S Sanabria Boh\u00f3rquez","year":"2019","unstructured":"Sanabria Boh\u00f3rquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, Tamagnan G, Alagille D, Ayalon G, Manser P, Bengtsson T, Ward M, Williams SP, Kerchner GA, Seibyl JP, Marek K, Weimer RM (2019) [18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 46:2077\u20132089","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4178_CR92","doi-asserted-by":"publisher","first-page":"e055090","DOI":"10.1002\/alz.055090","volume":"17","author":"PT Manser","year":"2021","unstructured":"Manser PT, Sanabria-Bohorquez S, Wildsmith KR, Toth B, Blendstrup M, Pickthorn K, Teng E (2021) A comparison of longitudinal [18F] GTP1 tau pet with other imaging and cognitive endpoints in the tauriel phase II study. Alzheimers Dement 17:e055090","journal-title":"Alzheimers Dement"},{"key":"4178_CR93","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1007\/s00259-020-04880-1","volume":"47","author":"ME Schmidt","year":"2020","unstructured":"Schmidt ME, Janssens L, Moechars D, Rombouts FJR, Timmers M, Barret O, Constantinescu CC, Madonia J, Russell DS, Sandiego CM, Kolb H (2020) Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 47:3176\u20133185","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4178_CR94","doi-asserted-by":"publisher","first-page":"18627","DOI":"10.1038\/s41598-020-73729-2","volume":"10","author":"M Noguchi-Shinohara","year":"2020","unstructured":"Noguchi-Shinohara M, Ono K, Hamaguchi T, Nagai T, Kobayashi S, Komatsu J, Samuraki-Yokohama M, Iwasa K, Yokoyama K, Nakamura H, Yamada M (2020) Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer\u2019s disease progression. Sci Rep 10:18627","journal-title":"Sci Rep"},{"key":"4178_CR95","doi-asserted-by":"publisher","first-page":"e0286523","DOI":"10.1371\/journal.pone.0286523","volume":"18","author":"EJ Davidowitz","year":"2023","unstructured":"Davidowitz EJ, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG (2023) Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice. PLoS ONE 18:e0286523","journal-title":"PLoS ONE"},{"key":"4178_CR96","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-018-0539-8","volume":"6","author":"C Giacomini","year":"2018","unstructured":"Giacomini C, Koo CY, Yankova N, Tavares IA, Wray S, Noble W, Hanger DP, Morris JDH (2018) A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies. Acta Neuropathol Commun 6:37\u201337","journal-title":"Acta Neuropathol Commun"},{"key":"4178_CR97","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1158\/1535-7163.MCT-17-0077","volume":"16","author":"C-Y Koo","year":"2017","unstructured":"Koo C-Y, Giacomini C, Reyes-Corral M, Olmos Y, Tavares IA, Marson CM, Linardopoulos S, Tutt AN, Morris JDH (2017) Targeting TAO kinases using a new inhibitor compound delays mitosis and induces mitotic cell death in centrosome amplified breast cancer cells. Mol Cancer Ther 16:2410\u20132421","journal-title":"Mol Cancer Ther"},{"key":"4178_CR98","unstructured":"Asceneuron (2021) https:\/\/www.asceneuron.com\/news\/asceneuron-awarded-alzheimers-drug-discovery-foundation"},{"key":"4178_CR99","unstructured":"(2023) https:\/\/www.pharmaceutical-technology.com\/data-insights\/biib-113-biogen-alzheimer-s-disease-likelihood-of-approval\/"},{"key":"4178_CR100","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/j.1471-4159.2009.06224.x","volume":"110","author":"W Li","year":"2009","unstructured":"Li W, Sperry JB, Crowe A, Trojanowski JQ, Smith AB 3rd, Lee VM (2009) Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J Neurochem 110:1339\u20131351","journal-title":"J Neurochem"},{"key":"4178_CR101","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/jcmm.13358","volume":"22","author":"M Campolo","year":"2018","unstructured":"Campolo M, Casili G, Lanza M, Filippone A, Paterniti I, Cuzzocrea S, Esposito E (2018) Multiple mechanisms of dimethyl fumarate in amyloid \u03b2-induced neurotoxicity in human neuronal cells. J Cell Mol Med 22:1081\u20131094","journal-title":"J Cell Mol Med"},{"key":"4178_CR102","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s12035-014-8705-x","volume":"50","author":"G Morris","year":"2014","unstructured":"Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, Maes M (2014) The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol 50:1059\u20131084","journal-title":"Mol Neurobiol"},{"key":"4178_CR103","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12964-021-00704-3","volume":"19","author":"SK Sonawane","year":"2021","unstructured":"Sonawane SK, Uversky VN, Chinnathambi S (2021) Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation. Cell Commun Signal 19:16","journal-title":"Cell Commun Signal"},{"key":"4178_CR104","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14756366.2017.1347783","volume":"32","author":"A Cornejo","year":"2017","unstructured":"Cornejo A, Aguilar Sandoval F, Caballero L, Machuca L, Mu\u00f1oz P, Caballero J, Perry G, Ardiles A, Areche C, Melo F (2017) Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to \u03b2 sheet in tau protein linked to Alzheimer\u2019s disease. J Enzyme Inhib Med Chem 32:945\u2013953","journal-title":"J Enzyme Inhib Med Chem"},{"key":"4178_CR105","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/med.20177","volume":"31","author":"M Oz","year":"2011","unstructured":"Oz M, Lorke DE, Hasan M, Petroianu GA (2011) Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev 31:93\u2013117","journal-title":"Med Res Rev"},{"key":"4178_CR106","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s002280000124","volume":"56","author":"C Peter","year":"2000","unstructured":"Peter C, Hongwan D, K\u00fcpfer A, Lauterburg BH (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 56:247\u2013250","journal-title":"Eur J Clin Pharmacol"},{"key":"4178_CR107","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1002\/anie.201208290","volume":"52","author":"E Akoury","year":"2013","unstructured":"Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M (2013) Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew Chem Int Ed 52:3511\u20133515","journal-title":"Angew Chem Int Ed"},{"key":"4178_CR108","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/sj.bjp.0707430","volume":"152","author":"RR Ramsay","year":"2007","unstructured":"Ramsay RR, Dunford C, Gillman PK (2007) Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 152:946\u2013951","journal-title":"Br J Pharmacol"},{"key":"4178_CR109","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","volume":"88","author":"CM Wischik","year":"2014","unstructured":"Wischik CM, Harrington CR, Storey JMD (2014) Tau-aggregation inhibitor therapy for Alzheimer\u2019s disease. Biochem Pharmacol 88:529\u2013539","journal-title":"Biochem Pharmacol"},{"key":"4178_CR110","doi-asserted-by":"publisher","first-page":"3245935","DOI":"10.1155\/2016\/3245935","volume":"2016","author":"F Panza","year":"2016","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G (2016) Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease. Biomed Res Int 2016:3245935","journal-title":"Biomed Res Int"},{"key":"4178_CR111","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JMD, Harrington CR, Wischik CM (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet 388:2873\u20132884","journal-title":"The Lancet"},{"key":"4178_CR112","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/00005072-199902000-00008","volume":"58","author":"R Morsch","year":"1999","unstructured":"Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58:188\u2013197","journal-title":"J Neuropathol Exp Neurol"},{"key":"4178_CR113","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/srep00700","volume":"2","author":"CA Lasagna-Reeves","year":"2012","unstructured":"Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2:700","journal-title":"Sci Rep"},{"key":"4178_CR114","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-6-39","volume":"6","author":"CA Lasagna-Reeves","year":"2011","unstructured":"Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6:39","journal-title":"Mol Neurodegener"},{"key":"4178_CR115","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-190465","volume":"73","author":"EJ Davidowitz","year":"2020","unstructured":"Davidowitz EJ, Krishnamurthy PK, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG (2020) In vivo validation of a small molecule inhibitor of tau self-association in htau mice. J Alzheimers Dis 73:147\u2013161","journal-title":"J Alzheimers Dis"},{"key":"4178_CR116","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1021\/acschemneuro.1c00235","volume":"12","author":"A Pasieka","year":"2021","unstructured":"Pasieka A, Panek D, Sza\u0142aj N, Espargar\u00f3 A, Wi\u0119ckowska A, Malawska B, Sabat\u00e9 R, Bajda M (2021) Dual inhibitors of amyloid-\u03b2 and tau aggregation with amyloid-\u03b2 disaggregating properties: extended in cellulo, in silico, and kinetic studies of multifunctional anti-Alzheimer\u2019s agents. ACS Chem Neurosci 12:2057\u20132068","journal-title":"ACS Chem Neurosci"},{"key":"4178_CR117","doi-asserted-by":"publisher","first-page":"113209","DOI":"10.1016\/j.ejmech.2021.113209","volume":"214","author":"D Malafaia","year":"2021","unstructured":"Malafaia D, Albuquerque HMT, Silva AMS (2021) Amyloid-\u03b2 and tau aggregation dual-inhibitors: a synthetic and structure-activity relationship focused review. Eur J Med Chem 214:113209","journal-title":"Eur J Med Chem"},{"key":"4178_CR118","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K SantaCruz","year":"2005","unstructured":"SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476\u2013481","journal-title":"Science"},{"key":"4178_CR119","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1471-4159.1993.tb03603.x","volume":"61","author":"CX Gong","year":"1993","unstructured":"Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61:921\u2013927","journal-title":"J Neurochem"},{"key":"4178_CR120","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1006\/abbi.1998.0813","volume":"357","author":"A Sengupta","year":"1998","unstructured":"Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 357:299\u2013309","journal-title":"Arch Biochem Biophys"},{"key":"4178_CR121","doi-asserted-by":"publisher","first-page":"34873","DOI":"10.1074\/jbc.M405131200","volume":"279","author":"ADC Alonso","year":"2004","unstructured":"Alonso ADC, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279:34873\u201334881","journal-title":"J Biol Chem"},{"key":"4178_CR122","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"CX Gong","year":"2008","unstructured":"Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15:2321\u20132328","journal-title":"Curr Med Chem"},{"key":"4178_CR123","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","volume":"12","author":"L Martin","year":"2013","unstructured":"Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F (2013) Tau protein kinases: involvement in Alzheimer\u2019s disease. Ageing Res Rev 12:289\u2013309","journal-title":"Ageing Res Rev"},{"key":"4178_CR124","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1091\/mbc.02-03-0046","volume":"13","author":"J Biernat","year":"2002","unstructured":"Biernat J, Wu Y-Z, Timm T, Zheng-Fischh\u00f6fer Q, Mandelkow E, Meijer L, Mandelkow E-M (2002) Protein kinase MARK\/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell 13:4013\u20134028","journal-title":"Mol Biol Cell"},{"key":"4178_CR125","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.neurobiolaging.2004.06.016","volume":"26","author":"GJ Ho","year":"2005","unstructured":"Ho GJ, Hashimoto M, Adame A, Izu M, Alford MF, Thal LJ, Hansen LA, Masliah E (2005) Altered p59Fyn kinase expression accompanies disease progression in Alzheimer\u2019s disease: implications for its functional role. Neurobiol Aging 26:625\u2013635","journal-title":"Neurobiol Aging"},{"key":"4178_CR126","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/jnr.10299","volume":"69","author":"T Town","year":"2002","unstructured":"Town T, Zolton J, Shaffner R, Schnell B, Crescentini R, Wu Y, Zeng J, Delledonne A, Obregon D, Tan J, Mullan M (2002) p35\/Cdk5 pathway mediates soluble amyloid-\u03b2 peptide-induced tau phosphorylation in vitro. J Neurosci Res 69:362\u2013372","journal-title":"J Neurosci Res"},{"key":"4178_CR127","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12031-011-9588-1","volume":"45","author":"SD Schlatterer","year":"2011","unstructured":"Schlatterer SD, Acker CM, Davies P (2011) c-Abl in neurodegenerative disease. J Mol Neurosci 45:445\u2013452","journal-title":"J Mol Neurosci"},{"key":"4178_CR128","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1046\/j.1471-4159.2000.0741587.x","volume":"74","author":"CH Reynolds","year":"2000","unstructured":"Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3\u03b2. J Neurochem 74:1587\u20131595","journal-title":"J Neurochem"},{"key":"4178_CR129","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","volume":"68","author":"PN Tariot","year":"2011","unstructured":"Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS (2011) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 68:853\u2013861","journal-title":"Arch Gen Psychiatry"},{"key":"4178_CR130","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"L Seren\u00f3","year":"2009","unstructured":"Seren\u00f3 L, Coma M, Rodr\u00edguez M, S\u00e1nchez-Ferrer P, S\u00e1nchez MB, Gich I, Agull\u00f3 JM, P\u00e9rez M, Avila J, Guardia-Laguarta C, Clarim\u00f3n J, Lle\u00f3 A, G\u00f3mez-Isla T (2009) A novel GSK-3beta inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis 35:359\u2013367","journal-title":"Neurobiol Dis"},{"key":"4178_CR131","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S, Boada M, Dubois B, H\u00fcll M, Rinne JO, Huppertz HJ, Calero M, Andr\u00e9s MV, G\u00f3mez-Carrillo B, Le\u00f3n T, del Ser T (2015) A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimers Dis 45:75\u201388","journal-title":"J Alzheimers Dis"},{"key":"4178_CR132","doi-asserted-by":"publisher","first-page":"15418","DOI":"10.1074\/jbc.M112.448183","volume":"288","author":"IA Tavares","year":"2013","unstructured":"Tavares IA, Touma D, Lynham S, Troakes C, Schober M, Causevic M, Garg R, Noble W, Killick R, Bodi I, Hanger DP, Morris JDH (2013) Prostate-derived Sterile 20-like Kinases (PSKs\/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease. J Biol Chem 288:15418\u201315429","journal-title":"J Biol Chem"},{"key":"4178_CR133","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/S0021-9258(17)43295-9","volume":"259","author":"CR Torres","year":"1984","unstructured":"Torres CR, Hart GW (1984) Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem 259:3308\u20133317","journal-title":"J Biol Chem"},{"key":"4178_CR134","doi-asserted-by":"publisher","first-page":"34472","DOI":"10.1074\/jbc.R114.601351","volume":"289","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Shan X, Yuzwa SA, Vocadlo DJ (2014) The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem 289:34472\u201334481","journal-title":"J Biol Chem"},{"key":"4178_CR135","doi-asserted-by":"publisher","first-page":"28741","DOI":"10.1074\/jbc.271.46.28741","volume":"271","author":"CS Arnold","year":"1996","unstructured":"Arnold CS, Johnson GVW, Cole RN, Dong DLY, Lee M, Hart GW (1996) The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem 271:28741\u201328744","journal-title":"J Biol Chem"},{"key":"4178_CR136","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.arr.2018.05.003","volume":"46","author":"TS Pinho","year":"2018","unstructured":"Pinho TS, Verde DM, Correia SC, Cardoso SM, Moreira PI (2018) O-GlcNAcylation and neuronal energy status: implications for Alzheimer\u2019s disease. Ageing Res Rev 46:32\u201341","journal-title":"Ageing Res Rev"},{"key":"4178_CR137","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/brain\/awp099","volume":"132","author":"F Liu","year":"2009","unstructured":"Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong C-X (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer\u2019s disease. Brain 132:1820\u20131832","journal-title":"Brain"},{"key":"4178_CR138","doi-asserted-by":"publisher","first-page":"15120","DOI":"10.1073\/pnas.1606899113","volume":"113","author":"AC Wang","year":"2016","unstructured":"Wang AC, Jensen EH, Rexach JE, Vinters HV, Hsieh-Wilson LC (2016) Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration. Proc Natl Acad Sci USA 113:15120\u201315125","journal-title":"Proc Natl Acad Sci USA"},{"key":"4178_CR139","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1126\/science.1058714","volume":"291","author":"L Wells","year":"2001","unstructured":"Wells L, Vosseller K, Hart GW (2001) Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291:2376\u20132378","journal-title":"Science"},{"key":"4178_CR140","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1006\/bbrc.1995.2149","volume":"213","author":"LS Griffith","year":"1995","unstructured":"Griffith LS, Schmitz B (1995) O-linked N-acetylglucosamine is upregulated in Alzheimer brains. Biochem Biophys Res Commun 213:424\u2013431","journal-title":"Biochem Biophys Res Commun"},{"key":"4178_CR141","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.bbadis.2014.05.014","volume":"1842","author":"S F\u00f6rster","year":"2014","unstructured":"F\u00f6rster S, Welleford AS, Triplett JC, Sultana R, Schmitz B, Butterfield DA (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim Biophys Acta 1842:1333\u20131339","journal-title":"Biochim Biophys Acta"},{"key":"4178_CR142","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nchembio.96","volume":"4","author":"SA Yuzwa","year":"2008","unstructured":"Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, Whitworth GE, Stubbs KA, McEachern EJ, Davies GJ, Vocadlo DJ (2008) A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4:483\u2013490","journal-title":"Nat Chem Biol"},{"key":"4178_CR143","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","volume":"79","author":"DL Graham","year":"2014","unstructured":"Graham DL, Gray AJ, Joyce JA, Yu D, O\u2019Moore J, Carlson GA, Shearman MS, Dellovade TL, Hering H (2014) Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology 79:307\u2013313","journal-title":"Neuropharmacology"},{"key":"4178_CR144","doi-asserted-by":"publisher","first-page":"e35277","DOI":"10.1371\/journal.pone.0035277","volume":"7","author":"Y Yu","year":"2012","unstructured":"Yu Y, Zhang L, Li X, Run X, Liang Z, Li Y, Liu Y, Lee MH, Grundke-Iqbal I, Iqbal K, Vocadlo DJ, Liu F, Gong CX (2012) Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS ONE 7:e35277\u2013e35277","journal-title":"PLoS ONE"},{"key":"4178_CR145","doi-asserted-by":"publisher","first-page":"10062","DOI":"10.1021\/acs.jmedchem.9b01090","volume":"62","author":"HG Selnick","year":"2019","unstructured":"Selnick HG, Hess JF, Tang C, Liu K, Schachter JB, Ballard JE, Marcus J, Klein DJ, Wang X, Pearson M, Savage MJ, Kaul R, Li T-S, Vocadlo DJ, Zhou Y, Zhu Y, Mu C, Wang Y, Wei Z, Bai C, Duffy JL, McEachern EJ (2019) Discovery of MK-8719, a potent O-GlcNAcase inhibitor as a potential treatment for tauopathies. J Med Chem 62:10062\u201310097","journal-title":"J Med Chem"},{"issue":"11","key":"4178_CR146","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1523\/JNEUROSCI.4922-11.2012","volume":"32","author":"B Zhang","year":"2012","unstructured":"Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB, Lee VM (2012) The microtubule-stabilizing agent, epothilone d, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32(11):3601\u20133611","journal-title":"J Neurosci"},{"key":"4178_CR147","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","volume":"11","author":"DP Fitzgerald","year":"2012","unstructured":"Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Silberman S, Palmieri D, Steeg PS (2012) TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 11:1959\u20131967","journal-title":"Mol Cancer Ther"},{"key":"4178_CR148","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1111\/jns.12336","volume":"24","author":"S Tamburin","year":"2019","unstructured":"Tamburin S, Park SB, Alberti P, Demichelis C, Schenone A, Argyriou AA (2019) Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24:S40\u2013S51","journal-title":"J Peripher Nerv Syst"},{"key":"4178_CR149","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0065-2571(94)90017-5","volume":"34","author":"AA Depaoli-Roach","year":"1994","unstructured":"Depaoli-Roach AA, Park IK, Cerovsky V, Csortos C, Durbin SD, Kuntz MJ, Sitikov A, Tang PM, Verin A, Zolnierowicz S (1994) Serine\/threonine protein phosphatases in the control of cell function. Adv Enzyme Regul 34:199\u2013224","journal-title":"Adv Enzyme Regul"},{"key":"4178_CR150","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3233\/JAD-2010-100987","volume":"23","author":"W Qian","year":"2011","unstructured":"Qian W, Yin X, Hu W, Shi J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX, Liu F (2011) Activation of protein phosphatase 2B and hyperphosphorylation of tau in Alzheimer\u2019s disease. J Alzheimers Dis 23:617\u2013627","journal-title":"J Alzheimers Dis"},{"key":"4178_CR151","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/0014-5793(94)80247-5","volume":"341","author":"CX Gong","year":"1994","unstructured":"Gong CX, Grundke-Iqbal I, Damuni Z, Iqbal K (1994) Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Lett 341:94\u201398","journal-title":"FEBS Lett"},{"key":"4178_CR152","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1432-1033.1983.tb07362.x","volume":"132","author":"TS Ingebritsen","year":"1983","unstructured":"Ingebritsen TS, Stewart AA, Cohen P (1983) The protein phosphatases involved in cellular regulation. Eur J Biochem 132:297\u2013307","journal-title":"Eur J Biochem"},{"key":"4178_CR153","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/jnen\/63.4.287","volume":"63","author":"E Sontag","year":"2004","unstructured":"Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White IIICL (2004) Altered expression levels of the protein phosphatase 2A AB\u03b1C enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63:287\u2013301","journal-title":"J Neuropathol Exp Neurol"},{"key":"4178_CR154","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0002-9440(10)62486-8","volume":"166","author":"H Tanimukai","year":"2005","unstructured":"Tanimukai H, Grundke-Iqbal I, Iqbal K (2005) Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer\u2019s disease. Am J Pathol 166:1761\u20131771","journal-title":"Am J Pathol"},{"key":"4178_CR155","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1074\/jbc.275.8.5535","volume":"275","author":"CX Gong","year":"2000","unstructured":"Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain: implications for neurofibrillary degeneration in Alzheimer\u2019s disease. J Biol Chem 275:5535\u20135544","journal-title":"J Biol Chem"},{"key":"4178_CR156","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.yjmcc.2016.11.003","volume":"101","author":"ER Lubbers","year":"2016","unstructured":"Lubbers ER, Mohler PJ (2016) Roles and regulation of protein phosphatase 2A (PP2A) in the heart. J Mol Cell Cardiol 101:127\u2013133","journal-title":"J Mol Cell Cardiol"},{"key":"4178_CR157","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cellsig.2006.11.013","volume":"19","author":"BJ Toole","year":"2007","unstructured":"Toole BJ, Cohen PTW (2007) The skeletal muscle-specific glycogen-targeted protein phosphatase 1 plays a major role in the regulation of glycogen metabolism by adrenaline in vivo. Cell Signal 19:1044\u20131055","journal-title":"Cell Signal"},{"key":"4178_CR158","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/10445490152717541","volume":"20","author":"J Loring","year":"2001","unstructured":"Loring J, Wen X, Lee J, Seilhamer J, Somogyi R (2001) A gene expression profile of Alzheimer\u2019s disease. DNA Cell Biol 20:683\u2013695","journal-title":"DNA Cell Biol"},{"key":"4178_CR159","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/exnr.2001.7630","volume":"168","author":"V Vogelsberg-Ragaglia","year":"2001","unstructured":"Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VMY (2001) PP2A mRNA expression is quantitatively decreased in Alzheimer\u2019s disease hippocampus. Exp Neurol 168:402\u2013412","journal-title":"Exp Neurol"},{"key":"4178_CR160","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/acn3.337","volume":"3","author":"HJ Park","year":"2016","unstructured":"Park HJ, Lee KW, Park ES, Oh S, Yan R, Zhang J, Beach TG, Adler CH, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM (2016) Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann Clin Transl Neurol 3:769\u2013780","journal-title":"Ann Clin Transl Neurol"},{"key":"4178_CR161","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.bmc.2017.08.040","volume":"26","author":"M Fontanillo","year":"2018","unstructured":"Fontanillo M, K\u00f6hn M (2018) Microcystins: synthesis and structure\u2013activity relationship studies toward PP1 and PP2A. Bioorg Med Chem 26:1118\u20131126","journal-title":"Bioorg Med Chem"},{"key":"4178_CR162","doi-asserted-by":"publisher","first-page":"13985","DOI":"10.1002\/anie.201606449","volume":"55","author":"M Fontanillo","year":"2016","unstructured":"Fontanillo M, Zemskov I, H\u00e4fner M, Uhrig U, Salvi F, Simon B, Wittmann V, K\u00f6hn M (2016) Synthesis of highly selective submicromolar microcystin-based inhibitors of protein phosphatase (PP)2A over PP1. Angew Chem Int Ed 55:13985\u201313989","journal-title":"Angew Chem Int Ed"},{"key":"4178_CR163","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/S0960-894X(03)00589-4","volume":"13","author":"BM Gulledge","year":"2003","unstructured":"Gulledge BM, Aggen JB, Chamberlin AR (2003) Linearized and truncated microcystin analogues as inhibitors of protein phosphatases 1 and 2A. Bioorg Med Chem Lett 13:2903\u20132906","journal-title":"Bioorg Med Chem Lett"},{"key":"4178_CR164","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/S0960-894X(03)00588-2","volume":"13","author":"BM Gulledge","year":"2003","unstructured":"Gulledge BM, Aggen JB, Eng H, Sweimeh K, Chamberlin AR (2003) Microcystin analogues comprised only of adda and a single additional amino acid retain moderate activity as PP1\/PP2A inhibitors. Bioorg Med Chem Lett 13:2907\u20132911","journal-title":"Bioorg Med Chem Lett"},{"key":"4178_CR165","first-page":"23","volume":"365","author":"M Swingle","year":"2007","unstructured":"Swingle M, Ni L, Honkanen RE (2007) Small-molecule inhibitors of ser\/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 365:23\u201338","journal-title":"Methods Mol Biol"},{"key":"4178_CR166","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.bmcl.2004.01.093","volume":"14","author":"ME Hart","year":"2004","unstructured":"Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A (2004) Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett 14:1969\u20131973","journal-title":"Bioorg Med Chem Lett"},{"key":"4178_CR167","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jocn.2010.04.020","volume":"17","author":"NM Corcoran","year":"2010","unstructured":"Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, Sundstrom LE, Costello AJ, Hovens CM (2010) Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer\u2019s disease model. J Clin Neurosci 17:1025\u20131033","journal-title":"J Clin Neurosci"},{"key":"4178_CR168","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3233\/JAD-160544","volume":"54","author":"CB Malpas","year":"2016","unstructured":"Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, Hicks RJ, Callahan J, Brodtmann A, Collins S, Macfarlane S, Corcoran NM, Hovens CM, Velakoulis D, O\u2019Brien TJ (2016) A phase IIa randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer\u2019s disease. J Alzheimers Dis 54:223\u2013232","journal-title":"J Alzheimers Dis"},{"key":"4178_CR169","first-page":"e12299","volume":"8","author":"L Vivash","year":"2022","unstructured":"Vivash L, Malpas CB, Meletis C, Gollant M, Eratne D, Li Q-X, McDonald S, O\u2019Brien WT, Brodtmann A, Darby D, Kyndt C, Walterfang M, Hovens CM, Velakoulis D, O\u2019Brien TJ (2022) A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer\u2019s Dement: Transl Res Clin Interv 8:e12299","journal-title":"Alzheimer\u2019s & Dementia: Transl Res Clin Interv"},{"key":"4178_CR170","doi-asserted-by":"publisher","first-page":"e075888","DOI":"10.1136\/bmjopen-2023-075888","volume":"13","author":"L Vivash","year":"2023","unstructured":"Vivash L, Johns H, Churilov L, MacPhail S, Casillas-Espinosa P, Malpas C, Shultz SR, Tailby C, Wijayath M, Reutens D, Gillinder L, Perucca P, Carney P, Nicolo JP, Lawn N, Kwan P, Velakoulis D, Hovens CM, O\u2019Brien TJ (2023) Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol. BMJ Open 13:e075888","journal-title":"BMJ Open"},{"key":"4178_CR171","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1172\/JCI65093","volume":"124","author":"A Gutierrez","year":"2014","unstructured":"Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, VerPlank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC (2014) Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest 124:644\u2013655","journal-title":"J Clin Invest"},{"key":"4178_CR172","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1016\/j.bmc.2015.07.007","volume":"23","author":"DB Kastrinsky","year":"2015","unstructured":"Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M (2015) Reengineered tricyclic anti-cancer agents. Bioorg Med Chem 23:6528\u20136534","journal-title":"Bioorg Med Chem"},{"key":"4178_CR173","doi-asserted-by":"publisher","first-page":"133454","DOI":"10.1016\/j.tet.2023.133454","volume":"140","author":"L Sheng","year":"2023","unstructured":"Sheng L, Bhalla R (2023) A template-based approach to the synthesis of 1,7-dioxaspiro[5.5]undecane spiroketal derivatives. Tetrahedron 140:133454","journal-title":"Tetrahedron"},{"key":"4178_CR174","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr3175","volume":"14","author":"LM Tseng","year":"2012","unstructured":"Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF (2012) CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 14:R68","journal-title":"Breast Cancer Res"},{"key":"4178_CR175","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/carcin\/bgt395","volume":"35","author":"Z Liu","year":"2013","unstructured":"Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W, Liu J, Zhou GB (2013) Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis 35:905\u2013914","journal-title":"Carcinogenesis"},{"key":"4178_CR176","doi-asserted-by":"publisher","first-page":"e1359","DOI":"10.1038\/cddis.2014.325","volume":"5","author":"HC Yu","year":"2014","unstructured":"Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiau CW, Chen KF (2014) Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis 5:e1359\u2013e1359","journal-title":"Cell Death Dis"},{"key":"4178_CR177","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.2337\/db15-0244","volume":"64","author":"LP Bharath","year":"2015","unstructured":"Bharath LP, Ruan T, Li Y, Ravindran A, Wan X, Nhan JK, Walker ML, Deeter L, Goodrich R, Johnson E, Munday D, Mueller R, Kunz D, Jones D, Reese V, Summers SA, Babu PVA, Holland WL, Zhang QJ, Abel ED, Symons JD (2015) Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo. Diabetes 64:3914\u20133926","journal-title":"Diabetes"},{"key":"4178_CR178","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/onc.2010.622","volume":"30","author":"CH Switzer","year":"2011","unstructured":"Switzer CH, Cheng RYS, Vitek TM, Christensen DJ, Wink DA, Vitek MP (2011) Targeting SET\/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30:2504\u20132513","journal-title":"Oncogene"},{"key":"4178_CR179","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2014.141","volume":"28","author":"R Pippa","year":"2014","unstructured":"Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD (2014) Effect of FTY720 on the SET\u2013PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 28:1915\u20131918","journal-title":"Leukemia"},{"key":"4178_CR180","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1042\/BJ20130263","volume":"453","author":"T Hyv\u00f6nen Mervi","year":"2013","unstructured":"Hyv\u00f6nen Mervi T, Koponen T, Weisell J, Pietil\u00e4 M, Khomutov Alex R, Veps\u00e4l\u00e4inen J, Alhonen L, Kein\u00e4nen Tuomo A (2013) Spermidine promotes adipogenesis of 3T3-L1 cells by preventing interaction of ANP32 with HuR and PP2A. Biochem J 453:467\u2013474","journal-title":"Biochem J"},{"key":"4178_CR181","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1073\/pnas.1015248108","volume":"108","author":"DA Bachovchin","year":"2011","unstructured":"Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Sch\u00fcrer SC, Nomura DK, Rosen H, Fu GC, Cravatt BF (2011) Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc Natl Acad Sci 108:6811\u20136816","journal-title":"Proc Natl Acad Sci"},{"key":"4178_CR182","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1021\/jm200502u","volume":"54","author":"DA Bachovchin","year":"2011","unstructured":"Bachovchin DA, Zuhl AM, Speers AE, Wolfe MR, Weerapana E, Brown SJ, Rosen H, Cravatt BF (2011) Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. J Med Chem 54:5229\u20135236","journal-title":"J Med Chem"},{"key":"4178_CR183","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1073\/pnas.1521018113","volume":"113","author":"RE Nicholls","year":"2016","unstructured":"Nicholls RE, Sontag JM, Zhang H, Staniszewski A, Yan S, Kim CY, Yim M, Woodruff CM, Arning E, Wasek B, Yin D, Bottiglieri T, Sontag E, Kandel ER, Arancio O (2016) PP2A methylation controls sensitivity and resistance to \u03b2-amyloid-induced cognitive and electrophysiological impairments. Proc Natl Acad Sci USA 113:3347\u20133352","journal-title":"Proc Natl Acad Sci USA"},{"key":"4178_CR184","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1523\/JNEUROSCI.2983-19.2020","volume":"40","author":"A Staniszewski","year":"2020","unstructured":"Staniszewski A, Zhang H, Asam K, Pitstick R, Kavanaugh MP, Arancio O, Nicholls RE (2020) Reduced expression of the PP2A methylesterase, PME-1, or the PP2A methyltransferase, LCMT-1, alters sensitivity to beta-amyloid-induced cognitive and electrophysiological impairments in mice. J Neurosci 40:4596\u20134608","journal-title":"J Neurosci"},{"key":"4178_CR185","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.biocel.2017.10.008","volume":"96","author":"CM O\u2019Connor","year":"2018","unstructured":"O\u2019Connor CM, Perl A, Leonard D, Sangodkar J, Narla G (2018) Therapeutic targeting of PP2A. Int J Biochem Cell Biol 96:182\u2013193","journal-title":"Int J Biochem Cell Biol"},{"key":"4178_CR186","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson A-S, Nilsson LNG, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE (2007) Sensitive ELISA detection of amyloid-\u03b2 protofibrils in biological samples. J Neurochem 103:334\u2013345","journal-title":"J Neurochem"},{"key":"4178_CR187","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 9:197\u2013210","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"4178_CR188","unstructured":"Eisai & Biogen (2022) Eisai presents full results of lecanemab phase 3 confirmatory clarity Ad study for early Alzheimer\u2019s disease at clinical trials on Alzheimer\u2019s disease (Ctad) conference. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/eisai-presents-full-results-lecanemab-phase-3-confirmatory"},{"key":"4178_CR189","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM, Investigators TA (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527","journal-title":"JAMA"},{"key":"4178_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104665","author":"HJ Yu","year":"2023","unstructured":"Yu HJ, Dickson SP, Wang PN, Chiu MJ, Huang CC, Chang CC, Liu H, Hendrix SB, Dodart JC, Verma A, Wang CY, Cummings J (2023) Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 2 study. eBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104665","journal-title":"eBioMedicine"},{"key":"4178_CR191","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-016-0177-y","volume":"8","author":"M Delnomdedieu","year":"2016","unstructured":"Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, Liu E, Ness S, Kupiec JW (2016) First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 8:12","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"4178_CR192","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/alz.12843","volume":"19","author":"EM Reiman","year":"2023","unstructured":"Reiman EM, Pruzin JJ, Rios-Romenets S, Brown C, Giraldo M, Acosta-Baena N, Tobon C, Hu N, Chen Y, Ghisays V, Enos J, Goradia DD, Lee W, Luo J, Malek-Ahmadi M, Protas H, Thomas RG, Chen K, Su Y, Boker C, Mastroeni D, Alvarez S, Quiroz YT, Langbaum JB, Sink KM, Lopera F, Tariot PN (2023) A public resource of baseline data from the Alzheimer\u2019s prevention initiative autosomal-dominant Alzheimer\u2019s disease trial. Alzheimer\u2019s Dement 19:1938\u20131946","journal-title":"Alzheimers Dement"},{"key":"4178_CR193","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/alzrt249","volume":"6","author":"T Leyhe","year":"2014","unstructured":"Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CA, Tong X, Yeo A, Khan S, Loercher A, Chalker M, Hottenstein C, Zetterberg H, Hilpert J, Mistry P (2014) Modulation of \u03b2-amyloid by a single dose of GSK933776 in patients with mild Alzheimer\u2019s disease: a phase I study. Alzheimer\u2019s Res Ther 6:19","journal-title":"Alzheimers Res Ther"},{"key":"4178_CR194","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS (2023) Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med 389:1096\u20131107","journal-title":"N Engl J Med"},{"key":"4178_CR195","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.20592","volume":"58","author":"M Lee","year":"2005","unstructured":"Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P (2005) A\u03b242 immunization in Alzheimer\u2019s disease generates A\u03b2 N-terminal antibodies. Ann Neurol 58:430\u2013435","journal-title":"Ann Neurol"},{"key":"4178_CR196","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M, Kong J, O\u2019Gorman J, Ratti E, Rajagovindan R, Viollet L, Huang E, Sharma S, Racine AM, Czerkowicz J, Graham D, Li Y, Hering H, Haeberlein SB (2023) TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nature Aging 3:1591\u20131601","journal-title":"Nature Aging"},{"key":"4178_CR197","first-page":"366","volume":"11","author":"W Luca","year":"2024","unstructured":"Luca W, Foster K, McClure K, Ahlijanian MK, Jefson M (2024) A Phase 1 single-ascending-dose trial in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous pnt001, a novel mid-domain tau antibody targeting cis-pT231 tau. J Prev Alzheimer\u2019s Dis 11:366\u2013374","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"4178_CR198","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","volume":"79","author":"E Teng","year":"2022","unstructured":"Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA, Investigators T (2022) Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol 79:758\u2013767","journal-title":"JAMA Neurol"},{"key":"4178_CR199","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N (2021) ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat Aging 1:521\u2013534","journal-title":"Nature Aging"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-024-04178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-024-04178-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-024-04178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:12:58Z","timestamp":1723086778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-024-04178-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":199,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["4178"],"URL":"https:\/\/doi.org\/10.1007\/s11064-024-04178-w","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}